地塞米松、干扰素对毛细支气管炎患儿的疗效观察被引量：3

下载PDF

导出

摘要目的观察地塞米松、干扰素对毛细支气管炎患儿反复喘息发作的疗效。方法2002年11月至2005年4月在儿科住院的46例毛细支气管炎患儿,按住院顺序随机分为地塞米松组和干扰素组各23例,分别采用地塞米松、干扰素治疗,观察喘息缓解情况及随访1年喘息反复发作次数。结果地塞米松组和干扰素组对毛细支气管炎患儿喘息缓解无显著差异(P>0.05),出院后随访1年喘息反复发作的例数有显著差异(P<0.05)。结论毛细支气管炎患儿存在TH1/TH2失衡,地塞米松短期内可起到抗炎作用,止喘起效快,但TH1/TH2治疗前后无显著差异,喘息反复出现、容易发展成婴幼儿哮喘。干扰素具有较强的免疫调节功能,提高机体细胞免疫,使TH1水平上升,调节TH1/TH2,对于治疗毛细支气管炎起到积极的作用,并对于预防婴幼儿哮喘具有重要意义。

作者王志文

机构地区中国铝业公司中州铝厂职工医院

出处《中国厂矿医学》 2007年第3期223-223,共1页 Chinese Medicine of Factory and Mine

关键词地塞米松干扰素毛细支气管炎辅助T细胞1/辅助T细胞2

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献3

1中华人民共和国卫生部.小儿肺炎防治方案[J].中华儿科杂志,1987,25:47-47.
2张艳敏,罗树舫,雷春莲,阎辉,成革胜.基因重组γ-型干扰素治疗小儿毛细支气管炎对T淋巴细胞调节作用的观察[J].中国实用儿科杂志,2002,17(10):611-613. 被引量：41
3王峥.毛细支气管炎的诊治和预防进展[J].国外医学（儿科学分册）,2003,30(3):126-129. 被引量：82

二级参考文献25

1Dudas RA, Karron RA. Respiratory syncytial virus vaccines[J]. Clin Microbiol Rev, 1998,11(3):430- 9.
2Walsh EE, McConnochie KM, Long CE, et al. Sewrity of respiratory syncytial virus infection is related to virus[I]. J Infect Dis,1997,175(4):814 - 20.
3Papadopoulos NG, Mouataki M, Tsolia M, et al. Association of rhinovirus infection with incazased disease seerity acute bronchiolitis strain[J]. Am J Respir Crit Care Med, 2002,165(9):1285-9.
4Sandritter TL, Kraua DM. Respiratory syncytial virus - immunoglobulin intravenous (RSV-IVIG) for respiratory syncytial viral infections[J]. J Pediatr Health Care, 1997,11(6):284-93.
5Lowther SA, Shay DK, Holman RC, et al. Bronchiolitis-assodated hospitalizations among American Indian and Alaska Native children[J]. Pediatr Infect Dis J, 2000,19(1):11-7.
6Wahab AA, Dawod ST, Raman HM. Clinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in Qatar[J]. J Trop Pediatr, 2001,47(6):363-6.
7Chan PW, Chew FT, Tan TN, et al. Seasonal variation in respiratory syncytial virus chest infection in the tropics[J]. Pediatr Pulmonol,2002,34(1):47- 51.
8Lanari M, Giovanrfini M, Giuffre L, et al. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity[J]. Pediatr Pulmonol,2002,33(6):458-65.
9Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective[J].Respir Med, 2002,96(Suppl B):S1-7.
10Openshaw PJ, Potential therapeutic implications of new insights into respiratory syncytial virus disease[J]. Respir Res, 2002,3(Suppl 1):S15-20.